Advanced search
Publication Cover
Expert Review of Clinical Immunology Volume 10, 2014 - Issue 10
Submit an article Journal homepage
367
Views
12
CrossRef citations to date
0
Altmetric
Drug Profiles

Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safety

David E JonesDepartment of Neurology, James Q. Miller MS Clinic, University of Virginia Health System, 500 Ray C. Hunt Drive, Charlottesville, VA 22908, USA
&
Myla D GoldmanCorrespondence[email protected]
Pages 1281-1291 | Published online: 22 Aug 2014

Citations (12)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Jan Dörr & Karl Baum. (2016) Alemtuzumab in the treatment of multiple sclerosis: patient selection and special considerations. Drug Design, Development and Therapy 10, pages 3379-3386.
Read now
Rachel Babij & Jai S Perumal. (2015) Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis. Neuropsychiatric Disease and Treatment 11, pages 1221-1229.
Read now

Articles from other publishers (10)

Louisa Müller-Miny, Michael Heming, Tobias Lautwein, Tobias Ruck, I-Na Lu, Heinz Wiendl & Gerd Meyer Zu Hörste. (2023) Alemtuzumab treatment exemplifies discordant immune effects of blood and cerebrospinal fluid in multiple sclerosis. Journal of Neuroimmunology 378, pages 578088.
Crossref
Z Li, S Richards, H K Surks, A Jacobs & M A Panzara. (2018) Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis. Clinical and Experimental Immunology 194:3, pages 295-314.
Crossref
Konstantin Huhn, Antonios Bayas, Sebastian Doerck, Benedikt Frank, Kathrin Gerbershagen, Kerstin Hellwig, Boris Kallmann, Christoph Kleinschnitz, Ingo Kleiter, De-Hyung Lee, Volker Limmroth, Mathias Mäurer, Sven Meuth, Peter Rieckmann, Tobias Ruck, Ralf Gold & Ralf A. Linker. (2018) Alemtuzumab as rescue therapy in a cohort of 50 relapsing–remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study. Journal of Neurology 265:7, pages 1521-1527.
Crossref
Reza Rahmanzadeh, Abdureza N. Moghadasi, Samira Navardi, Alireza Minagar & Mohammad A. Sahraian. 2018. Neuroinflammation. Neuroinflammation 1 20 .
Diana L Vargas & William R Tyor. (2023) Update on Disease-Modifying Therapies for Multiple Sclerosis. Journal of Investigative Medicine 65:5, pages 883-891.
Crossref
Faye A. H. Cooles, Amy E. Anderson, Tracey Drayton, Rachel A. Harry, Julie Diboll, Lee Munro, Nishanthi Thalayasingham, Andrew J. K. Östör & John D. Isaacs. (2016) Immune reconstitution 20 years after treatment with alemtuzumab in a rheumatoid arthritis cohort: implications for lymphocyte depleting therapies. Arthritis Research & Therapy 18:1.
Crossref
P. Kolber, F. Luessi, S.G. Meuth, L. Klotz, T. Korn, C. Trebst, B. Tackenberg, B. Kieseier, T. Kümpfel, V. Fleischer, H. Tumani, B. Wildemann, M. Lang, P. Flachenecker, U. Meier, W. Brück, V. Limmroth, A. Haghikia, H.-P. Hartung, M. Stangel, R. Hohlfeld, B. Hemmer, R. Gold, H. Wiendl & F. Zipp. (2015) Aktuelles zur Therapieumstellung bei Multipler SkleroseCurrent aspects of therapy conversion for multiple sclerosis. Der Nervenarzt 86:10, pages 1236-1247.
Crossref
Lilyana Amezcua, Mark J. Morrow & Guy V. Jirawuthiworavong. (2015) Multiple sclerosis. Current Opinion in Ophthalmology, pages 1.
Crossref
Tobias Ruck, Stefan Bittner, Heinz Wiendl & Sven Meuth. (2015) Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond. International Journal of Molecular Sciences 16:7, pages 16414-16439.
Crossref
Laure Michel, Catherine Larochelle & Alexandre Prat. (2015) Update on treatments in multiple sclerosis. La Presse Médicale 44:4, pages e137-e151.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.